BioSpace News Archive

GRI Bio, Inc. today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.

Entera Bio Ltd. announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR).

NRx Pharmaceuticals, Inc. today announced that the Company has achieved data-lock in its Phase 2b /3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101.

Lucid Diagnostics Inc. today announced that Lucid’s President & Chief Operating Officer Shaun O’Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 11:00 a.m. E.T.

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data presentations, as well as a sponsored symposium at the International Society of Nephrology’s World Congress of Nephrology.

RenovoRx, Inc. today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177 Lu-rhPSMA-10.1 for Treatment of Prostate Cancer.

Quanta Therapeutics announced the presentation of QTX3544, a multi-KRAS inhibitor with G12V-preferring activity (G12V+ multi-KRAS), in a late-breaking poster presentation session at the American Association of Cancer Research (AACR) Annual Meeting.

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the publication of a new study, highlighting the effectiveness of Lunit INSIGHT MMG in significantly reducing radiologists’ workload while enhancing cancer detection rates.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS ® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS).